Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has entered into an Asset Purchase and Settlement Agreement with Commave Therapeutics SA, under which Commave will purchase Zevra's serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for a total of $50 million. The agreement, effective March 13, 2026, resolves ongoing litigation between the two companies related to their previous collaboration and license agreement. Commave will pay Zevra $25 million upon execution of the agreement, followed by $20 million within ten business days, and the remaining $5 million upon delivery of specific manufacturing records. This transaction is expected to enhance Zevra's financial position, as the company recently repaid its outstanding obligations under a $63 million credit agreement, resulting in a debt-free balance sheet. Zevra's CEO, Neil F. McFarlane, expressed confidence in the agreement, highlighting the productive partnership with Commave and the focus on advancing therapies for rare diseases. The sale also includes a worldwide, royalty-free license for Commave to develop and commercialize SDX products under Zevra's retained patents and know-how. The companies plan to file a stipulation of dismissal with prejudice for the litigation within three business days following the agreement's effective date.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.